An observational study in Palliative Care and Supportive Care, sponsored by Norfolk and Norwich University Hospitals NHS Foundation Trust. Enrolling by invitation at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Norfolk and Norwich University Hospitals NHS Foundation Trust · Observational
To understand the clinical utility of multi-gene pharmacogenetic testing in patients receiving palliative and supportive care across palliative care settings (inpatient hospital, outpatient), specifically to calculate a drug-gene interaction ratio, based on extant prescriptions paired with an individual's pharmacogenetic results.
This is a prospective, observational cross-sectional study of patients with serious and/or life limiting condition conditions, such as incurable cancer undergoing palliative or supportive care treatment at a University Teaching Hospital in England, UK. Participants will be recruited at point of referral to in-patient or outpatient palliative care services (i.e. at point of presentation with symptom control issues).
All participant study activities:
All participants will undergo testing of a panel of genetic variants relevant to drugs used in symptom control (see https://cpicpgx.org/genes-drugs/ ). This will involve collecting a 5mL blood sample (the intervention) from individuals. All participants will be consented to examination of their records within local hospitals and/or primary care to extract study relevant data (described below).
The start of follow-up will be from the date of the blood sample (the intervention). Standard demographic information including ethnicity will be collected at baseline.
Participation in study will be for the duration of being under palliative care treatment, up to a maximum of 90days from recruitment date.
All participant sample will be stored and genetic analysis will take place after the end of recruitment and health data collection.
The study team will then calculate a drug-gene interaction ratio (DGI) (i.e. The total number of genetic variation results that pair with a relevant prescribed medication for that same individual, divided by total number of individuals tested).
Norfolk and Norwich University Hospitals NHS Foundation Trust is the lead sponsor of 30 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will be from Norfolk and Norwich University Hospitals NHS Foundation Trust
Inclusion Criteria: Aged 18 or older; incurable, life limiting condition, clinical care provided at NNUH.
Exclusion Criteria: Lacking capacity to consent to research (unless there is an appropriate consultee)
Patients with serious and/or life limiting condition conditions, such as incurable cancer undergoing palliative or supportive care treatment. They will have a 5mL blood sample collected.
Drug-gene interaction ratio (DGI)
The total number of genetic variation results that pair with a relevant prescribed medication for that same individual, divided by total number of individuals tested.
Time frame: This will be calculated for all current medications prescribed at the point of recruitment.
Frequency of changes in prescription medication that are potentially affected by drug-gene interaction
Number of participants who have a change in prescribed medication (dose or formulation) during 90 day follow up period that could be theoretically paired to possession of a clinically relevant drug-gene interaction
Time frame: from enrolment until 90 days post blood test
Started May 2025 (actual). Primary completion is estimated for Apr 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norfolk and Norwich University Hospitals NHS Foundation Trust